Enhabit (EHAB) Q1 2025 Earnings Call Transcript

Consolidated net revenue of $259.9M with consolidated adjusted EBITDA of $26.6M (+6.0% sequential; +5.1% YoY) and a 10.2% EBITDA margin (+60 bps). Home health revenue was $200.6M with adjusted EBITDA $38.3M (+7.9% sequential) driven by +3.7% ADC and lower visits per episode (13.9, -6.7% YoY); hospice revenue was $59.3M (+20.5% YoY) with adjusted EBITDA $15.0M and ADC 38.09 (+12.3% YoY) delivering a 25.3% segment margin. Balance sheet improved: free cash flow ~$17M (63.5% conversion), $25M bank debt paydown (including $20M Medalogix sale proceeds), liquidity $111M and leverage 4.4x (below 4.5x covenant); management reaffirmed 2025 guidance.

Analysis

The company's shift into episodic and value-based payer arrangements is the strategic lever with the largest second‑order upside: fewer visits per episode paired with higher effective yield creates embedded capacity that can be redeployed into higher‑margin hospice beds or new de‑novo openings without linear hiring. That creates a quasi-operating gearing where modest incremental admissions can flow disproportionately to EBITDA, but it also raises counterparty concentration and renegotiation risk as a growing share of economics sits in bespoke contracts with finite terms and quality gates.

Wider rollout of predictive analytics and branch rationalization materially change unit economics but introduce new operational vectors for downside: over‑optimization of visits can create quality or recertification friction that attracts audits or suppresses conversions long enough to negate short‑term margin gains. Similarly, outsourcing coding and consolidating branches reduces fixed cost but transfers execution risk to vendors and central teams, increasing sensitivity to coding accuracy, payer audits, and local referral relationships.

Improved free cash flow dynamics and early balance‑sheet relief create optionality for tuck‑ins and refinancing, compressing the path to normalized leverage levels and better credit pricing. Near‑term catalysts that will re‑rate the story higher are successful renegotiations of the largest value contracts, sustained hospice ADC momentum through consecutive quarters, and demonstrable retention of clinical outcomes post‑visit optimization; tail risks are payer pushback on episodic rates, labor market re‑acceleration, and coding/audit reversals that could reverse margin trends within a single quarter.

Key Decisions for Investors

• Core long EHAB (6–12 month horizon): initiate a modest-sized position (~2–3% portfolio). Use a protective hedge (buy 6‑month put ~15% OTM) to cap downside from an adverse payer renegotiation or coding/audit shock. Rationale: asymmetric upside from margin gearing and deleveraging optionality; hedge keeps maximum drawdown to manageable levels.
• Option spread to amplify upside with defined risk (9–12 month): buy a call spread (long front‑month LEAP call, short a higher strike) sized to equal 1–2% delta exposure. Aim for strikes ~30–40% above current spot to limit premium decay. Risk limited to premium; reward ~2–4x if company converts capacity into sustained EBITDA growth or announces tuck‑in M&A.
• Event contingency trade / monitoring rule: if management announces unfavorable outcomes in >1 major payer renegotiation or a material coding/audit reserve, buy short‑dated protective puts and reduce gross exposure; conversely, if leverage guidance is tightened or a small tuck‑in is announced that accelerates EBITDA conversion, add to equity position and unwind hedges. Set alerts on three KPIs: payer renegotiation outcomes, visits‑per‑episode stabilization, and coding/audit notices.